Mark Breidenbach
Stock Analyst at Oppenheimer
(1.62)
# 3,224
Out of 4,761 analysts
63
Total ratings
30.65%
Success rate
-0.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $16.87 | +77.83% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $2.17 | +499.08% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.72 | +888.37% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $17.77 | +434.61% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.76 | +1,320.45% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $1.32 | +657.58% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $12 | $0.80 | +1,393.47% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.59 | +4,356.82% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $2.10 | +233.33% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.31 | +2,342.75% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $0.17 | +7,358.41% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $5.78 | +159.52% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.36 | +8,723.53% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $1.38 | +1,566.67% | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $2.95 | +330,408.47% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2,700 | $4.08 | +66,076.47% | 3 | Dec 13, 2019 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $16.87
Upside: +77.83%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $2.17
Upside: +499.08%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.72
Upside: +888.37%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $17.77
Upside: +434.61%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $1.76
Upside: +1,320.45%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $1.32
Upside: +657.58%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $0.80
Upside: +1,393.47%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.59
Upside: +4,356.82%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $2.10
Upside: +233.33%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.31
Upside: +2,342.75%
Mar 3, 2023
Maintains: Outperform
Price Target: $15 → $13
Current: $0.17
Upside: +7,358.41%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $5.78
Upside: +159.52%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.36
Upside: +8,723.53%
Apr 26, 2021
Initiates: Outperform
Price Target: $23
Current: $1.38
Upside: +1,566.67%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $2.95
Upside: +330,408.47%
Dec 13, 2019
Upgrades: Outperform
Price Target: $2,700
Current: $4.08
Upside: +66,076.47%